Weight loss following testosterone treatment in hypogonadal men

July 2013

Long-term treatment of hypogonadal men with testosterone produces substantial and sustained weight loss. Saad F, Haider A, Doros G, et al. Obes 2013; 21(10): 1975−1981.

Obesity is a global public health problem reaching epidemic levels and has a huge impact on overall health, reduced quality of life and premature death. Testosterone (T) plays an important role in modulating adipogenesis and metabolism of carbohydrates and fats, and reduced plasma T levels have been associated with obesity and type 2 diabetes. However, treatment of obese subjects with T has resulted in marked decreases in fat mass, increases in lean body mass and improved sensitivity to insulin. Furthermore, T treatment in hypogonadal men has resulted in improvements in various cardiovascular parameters including serum LDL-cholesterol, blood pressure and heart rate.

The effect of T treatment on anthropometric parameters was investigated in 255 men being treated with testosterone therapy. This study was not designed to treat obesity or induce weight loss but rather examined measures of obesity recorded in hypogonadal men receiving T treatment for various medical conditions. The men were between 33 and 69 years of age, however, they were predominantly elderly (mean age, 58 years). Data were collected from patients treated in a single urologist’s office and all received treatment with parenteral testosterone undecanoate (TU) 1,000 mg. The study reported changes in body weight, body mass index (BMI) and waist circumference following long-term T treatment for up to 5 years. This study has the longest duration to date of any study using testosterone in hypogonadal men.


  • Low T has been associated with the development of obesity and other related conditions such as type 2 diabetes1,2
  • Lifestyle changes (diet and exercise) are typically recommended by physicians to combat obesity but weight loss is often modest and not sustainable over long periods of time3-5
  • The effect of testosterone therapy on weight and waist circumference was assessed in hypogonadal men receiving treatment for various medical conditions over a period of up to 5 years. The study reported substantial reductions in body weight, BMI and waist circumference following long-term treatment with T, and these reductions continued year after year over the 5-year observation period. Significant and marked weight loss occurred in almost all patients (95%). No significant weight gain was observed in obese or overweight men
    1. Body weight decreased from 106.2 ± 16.9 kg to 90.1 ± 9.5 kg with a mean loss of 15.4 ± 0.4 kg (Figure 1)
    2. A reduction in waist circumference was observed in 97% of patients, declining from 107.2 ± 9.1 cm to 98.5 ± 7.4 cm
    3. The reductions in body weight and waist circumference were statistically significant at the end of each year compared with the previous year, over the 5-year study duration (p<0.0001)
    4. A consistent and progressive decrease in BMI was also observed year after year during the 5-year observation period. At baseline BMI was 33.9 ± 5.5 and decreased to 32.4 ± 4.9 after 1 year, 31.3 ± 4.6 after 2 years, 30.6 ± 4.1 after 3 years, 30.2 ± 3.8 after 4 years and 29.1 ± 3.1 kg/m2 after 5 years
    5. The decline in BMI was most marked in obese men, followed by overweight men but with minimal changes observed in men whose BMI was within the normal range at baseline
    6. Moderate weight gain was observed only in men with normal weight at baseline, all of whom had co-morbidities including Crohn’s disease, ulcerative colitis, leukemia and Hodgkin’s lymphoma
  • The potential benefit and contribution of T treatment in combating obesity in hypogonadal men is new and unexpected, as such profound effects of T treatment on weight had not previously been reported. Previous T studies have been short-term and thus showed no or only modest effects on weight
    1. To date, studies with T have consistently shown that T treatment decreased fat mass and increased lean body weight6-9
    2. One of the longest studies, a 3-year placebo-controlled pilot study in men treated with TU, reported a decrease in waist circumference (a reliable indicator of visceral obesity) of 13 cm10
  • Combined with lifestyle changes, T may be a useful tool for facilitating weight loss in hypogonadal men

What is known

Obesity is a global health concern, growing to epidemic levels and leading to extensive health problems and morbidity.11 T plays a crucial role in energy utilization via a number of metabolic pathways1,12 and it upregulates various enzymes and transcriptional factors involved in metabolic function, particularly in mitochondria.13 T is known to inhibit lipoprotein lipase activity and triglyceride uptake resulting in rapid turnover of triglycerides and mobilization of lipids. Treatment with T has consistently shown a decrease in fat mass and increase in lean body mass.6-9 In addition, as T treatment is known to improve mood and alleviate fatigue, the patient is more motivated to pursue an active lifestyle, thus further increasing energy expenditure and contributing to weight loss. Interest in T treatment has grown recently following findings in pre-clinical and clinical studies that have implicated a role for T in the development of obesity.

What this study adds

This is the first study to report that T may have profound effects in facilitating weight loss in hypogonadal men. The magnitude of the weight loss observed in this study was unexpected as it was not designed to treat obesity or induce weight loss but rather examined measures of obesity recorded in hypogonadal men receiving T treatment for various medical conditions.

Earlier studies have been conducted over a relatively short time period, partly because the duration of placebo-controlled designed trials is limited by the risks of withholding treatment in patients with hypogonadism for long time periods. This present study was an observational study that assessed the association of T treatment and weight loss and included ‘real world’ data collected over the longest time period to date (5 years). Although the study was based on observational data, these data are considered robust as weight loss had not been expected and therefore men were not influenced by any suggestion that they may lose weight. Furthermore, the patients were not selected for any criteria other than hypogonadism; they presented with various comorbidities or were referred by other specialists with a suspicion of hypogonadism (e.g. osteoporosis).

This study reported substantial reductions in body weight, BMI and waist circumference following long-term treatment with T and these reductions were consistent and progressive over the 5-year observation period. Significant and marked weight loss occurred in almost all patients (95%) with the largest reductions in obese men at baseline.

Therefore, T therapy may be a useful tool to aid management of obesity in hypogonadal men. Nonetheless, long-term safety studies in hypogonadal men are required to provide further evidence that T is a safe and effective treatment to facilitate weight loss in this patient group.

Reduction in body weight (kg) in hypogonadal men in response to testosterone treatment over the course of 60 months

Figure 1: Reduction in body weight (kg) in hypogonadal men in response to testosterone treatment over the course of 60 months


  • Dhindsa S, Miller MG, McWhirter CL, et al. Testosterone concentrations in diabetic and nondiabetic obese men. Diabetes Care 2010;33(6):1186−1192. Return to content
  • Dhindsa S, Prabhakar S, Sethi M, et al. Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes. J Clin Endocrinol Metab 2004;89(11):5462−5468. Return to content
  • Appel LJ, Clark JM, Yeh HC, et al. Comparative effectiveness of weight-loss interventions in clinical practice. N Engl J Med 2011;365(21):1959−1968. Return to content
  • Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346(6):393−403. Return to content
  • Wadden TA, Volger S, Sarwer DB, et al. A two-year randomized trial of obesity treatment in primary care practice. N Engl J Med 2011;365(21):1969−1979. Return to content
  • Allan CA, Strauss BJ, Burger HG, et al. Testosterone therapy prevents gain in visceral adipose tissue and loss of skeletal muscle in nonobese aging men. J Clin Endocrinol Metab 2008;93(1):139−146. Return to content
  • Bhasin S, Travison TG, Storer TW, et al. Effect of testosterone supplementation with and without a dual 5alpha-reductase inhibitor on fat-free mass in men with suppressed testosterone production: a randomized controlled trial. JAMA 2012;307(9):931−939. Return to content
  • Srinivas-Shankar U, Roberts SA, Connolly MJ, et al. Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab 2010;95(2):639−650. Return to content
  • Svartberg J, Agledahl I, Figenschau Y, et al. Testosterone treatment in elderly men with subnormal testosterone levels improves body composition and BMD in the hip. Int J Impot Res 2008;20(4):378−387. Return to content
  • Saad F, Aversa A, Isidori AM, et al. Testosterone as potential effective therapy in treatment of obesity in men with testosterone deficiency: a review. Curr Diabetes Rev 2012;8(2):131−143. Return to content
  • Gluckman PD, Hanson M, Zimmet P, et al. Losing the war against obesity: the need for a developmental perspective. Sci Transl Med 2011;3(93):93cm19. Return to content
  • Traish AM, Guay A, Feeley R, et al. The dark side of testosterone deficiency: I. Metabolic syndrome and erectile dysfunction. J Androl 2009;30(1):10−22. Return to content
  • Traish AM, Abdullah B, Yu G. Androgen deficiency and mitochondrial dysfunction: implications for fatigue, muscle dysfunction, insulin resistance, diabetes, and cardiovascular disease. Horm Mol Biol Clin Invest 2011;8(1):431−444. Return to content